New Research Highlights Role of Lifestyle Factors, New Treatment Strategies in Cancer Care

Latest Advances Part of 2026 ASCO Annual Meeting Press ProgramLatest Advances Part of 2026 ASCO Annual Meeting Press Program

EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Monday, May 18, 5:30-7:00 PM (ET)
For credentialed media, an embargoed virtual press briefing will be held prior to the May 21 release of regular abstracts, featuring the following studies. The embargo on these studies will lift on Thursday, May 21 at 5:00 PM (ET):

• Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial (Abstract 5517)
• Can GLP-1 receptor agonists mitigate cancer progression?: A propensity-matched analysis across seven solid tumors (Abstract 3143)
• YOCAS yoga, mood disturbance, and insomnia: A URCC NCORP RB nationwide, phase III, randomized, controlled trial with cancer survivors (Abstract 12004)
• Effect of a weight loss intervention on quality of life and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial (Abstract 12010)
• Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology (Abstract 5005)

EMBARGOED PRE-MEETING PRESS BRIEFING (VIRTUAL EVENT) – Tuesday, May 26, 3:30-5:00 PM (ET)
Several Late-Breaking Abstracts (LBAs) being presented on Saturday, May 30, at the Meeting will be discussed in an embargoed virtual press briefing for credentialed media on May 26. The embargo will lift on these studies on Saturday, May 30 at 7:00 AM (CT)/8:00 AM (ET):

• Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial (Abstract LBA503)
• NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection test in population screening (Abstract LBA100)
• frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma (Abstract LBA7000)
• Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases (Abstract LBA2000)

EMBARGOED ONSITE PRESS BRIEFING – Saturday, May 30, 8:00-9:30 AM CT/9:00-10:30 AM ET
Two press briefings will be held onsite during the Annual Meeting and will highlight LBAs being presented during the meeting. The press briefings will be held in person and available virtually via Zoom for credentialed reporters covering the Meeting remotely. The first of these briefings will take place on Saturday, May 30. The embargo will lift on these LBAs on Sunday, May 31 at 7:00 AM (CT)/8:00 AM (ET):

• Final analysis of PROTEUS, a phase 3 randomized, double-blind, placebo–controlled study of perioperative (neoadjuvant and adjuvant) apalutamide (APA) plus androgen deprivation therapy (ADT) versus ADT with radical prostatectomy (RP) in men with high-risk localized prostate cancer (HRLPC) (Abstract LBA1)
• SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma (Abstract LBA2)
• Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial (Abstract LBA3)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial (Abstract LBA4)
• Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma: Primary analysis from the phase 3 RASolute 302 study (Abstract LBA5)
• Ultra-Low-Dose Immunotherapy Plus Oral Metronomic Chemotherapy Versus Paclitaxel-Carboplatin in Platinum-Sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Randomized Phase III Trial (Abstract LBA6007)

EMBARGOED ONSITE PRESS BRIEFING  – Sunday, May 31, 8:00-9:30 AM CT/9:00-10:30 AM ET
The second onsite press briefing will take place on Sunday, May 31. The embargo will lift on these LBAs on either Monday, June 1, or Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET):

• SUPPORT+ digital self‑management and clinical support for advanced cancer: A randomized controlled trial (Abstract LBA12008)
  Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)
• Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in participants with embolization-eligible unresectable hepatocellular carcinoma (Abstract LBA4000)
  Embargo lifts Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET)
• Progression-free survival after next line of treatment and subsequent therapies in the ASCENT-04 study of participants with previously untreated PD-L1+ metastatic triple-negative breast cancer treated with sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembro (Abstract LBA1000)
  Embargo lifts Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET)

All press briefings will also be recorded and made available to credentialed reporters for a period of seven days following the briefing in ASCO’s Media Headquarters.

ADDITIONAL STUDIES OF NOTE 
The following studies will be included in the official ASCO Tip Sheet, a brief summary of additional noteworthy research. The Tip Sheet will be sent to credentialed reporters ahead of the Meeting and will include additional comments from the lead authors and ASCO experts.

The embargo will lift Thursday, May 21, at 5:00 PM (ET) for the following studies:

• Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023) (Abstract 5503)
• Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial (Abstract 3507)
• Efficacy of YES, an mHealth intervention for adolescent and young adults with breast cancer, to address AYA survivorship concerns (Abstract 12009)
• Prevalence of symptomatic skeletal events with reduced denosumab dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE (Abstract 1004)
• Phase 3 trial of trastuzumab rezetecan vs standard of care for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (Abstract 3505)
• Efficacy and safety of giredestrant in patients with estrogen receptor–positive, HER2-negative early breast cancer in the phase III lidERA BC clinical trial: Results by menopausal status (Abstract 502)
• GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety (Abstract 10520)
• Digital health intervention for comorbid insomnia and neurocognitive impairment in adult survivors of childhood cancer: Results from a randomized clinical trial (Abstract 10003)
• Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients (Abstract 629)
• Association of GLP-1 agonists with breast cancer incidence in women (Abstract 10506)
• Progression-free survival after next line of treatment and subsequent therapies in the ASCENT-03 study of participants with previously untreated metastatic triple-negative breast cancer treated with sacituzumab govitecan vs chemotherapy (Abstract 1001)
• Izalontamab brengitecan versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma: A multicenter, randomized, open-label, phase III study (Abstract 4008)
  
• First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500)
• MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients (pts) with relapsed refractory multiple myeloma (Abstract 7507)

The embargo will lift Friday, May 29 at 7:00 AM (CT)/8:00 AM (ET) for the following study:

• Mezigdomide, carfilzomib, and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: Results from the phase 3 SUCCESSOR-2 trial (Abstract LBA7506)

The embargo will lift Saturday, May 30 at 7:00 AM (CT)/8:00 AM (ET) for the following studies:

• First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p in predicting active germ cell malignancy in patients with early stage testicular cancer (Abstract LBA5003)
• Efficacy and Safety of Asandeutertinib versus Osimertinib as First-line Treatment in EGFR-Mutated NSCLC Patients with Brain Metastases: Interim Analysis of an Open-Label, Multicenter, Randomized, Pivotal Phase II Study (ESAONA) (Abstract LBA2007)
• TALAPRO-3: Talazoparib + enzalutamide compared with placebo + ENZA for the treatment of patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations (Abstract LBA5007)

The embargo will lift Monday, June 1 at 7:00 AM (CT)/8:00 AM (ET) for the following study:

• Darovasertib in combination with crizotinib versus investigator’s choice as first-line treatment for patients with HLA-A2–negative metastatic uveal melanoma: Results from the phase 2/3 OptimUM-02 study (Abstract LBA9503)

The embargo will lift Tuesday, June 2 at 7:00 AM (CT)/8:00 AM (ET) for the following studies:

• Izalontamab Brengitecan Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer: A Randomized Phase III Study (Abstract LBA1003)
• First-line camizestrant for emergent ESR1 mutations in advanced breast cancer: Final progression-free survival 2from the Phase III SERENA-6 trial (Abstract LBA1007)
• Giredestrant + palbociclib vs letrozole + PALBO as first-line therapy in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer: Primary analysis of the phase III persevERA BC trial (Abstract LBA1006)

ASCO 2026, Nieuw onderzoek benadrukt de rol van leefstijlfactoren en nieuwe behandelstrategieën in de kankerzor

---

• ASCO 2024: abstracten van ASCO 2024 gerelateerd aan alvleesklierkanker en galwegenkanker copy 1

---

• Aanbevolen abstracten voor vormen van spijsverteringskanker waaronder alvleesklierkanker, darmkanker en maagkanker van ASCO 2019 copy 1

---

• Regulier - alvleesklierkanker - pancreaskanker: actuele ontwikkelingen en belangrijke studies binnen de reguliere oncologie: een overzicht